Corona's Vaccine: Big News Human Trial Rohtak PGI Phase I Successful

Attempts to control the coronavirus have been successful. The first phase of the trial of the Corona's vaccine has been successful. PGI physicians have now dosed six people in Part Two of the first phase after the approval of the Safety Control Board. In the first part, 20 people were given vaccine doses and six of them were found to be very well. Report of other people is awaited. Now 25 more people are ready to give doses. Preparations have also been started to give the second dose to the people giving vaccine in the first part next week.

Corona's Vaccine: Big News Human Trial Rohtak PGI Phase I Successful

In the second part, about 30 people will be given vaccine for trial in PGIMS.

The trial of the corona vaccine started on July 17 at PGIMS (Pandit Bhagwat Dayal Sharma Medical University). For the trial, Dr. Savita Verma, Professor, Department of Pharmacology, was appointed Principal Investigator, Dr. Ramesh Verma, Professor, Department of Community Medicine, and Dr. Dhruv Chaudhary, Professor, Department of Pulmonary Critical Care Medicine, were appointed as Assistant Investigators.

So far, 20 volunteers have been screened for the second part in PGI

During the trial, on the instructions of DCGI (Drug Controller General of India), in the first phase, 20 people were given vaccine doses in PGI as against 50 people across the country. After giving the vaccine, all volunteers are in good health. Its report was sent by doctors to the Safety Control Board and DCGI. On behalf of the Safety Control Board, the vaccine has been declared safe and it has been approved to proceed with the trial.

Vaccine given to six, will be decided after investigation report of ten

Now physicians have started trial under the second part of the first phase. Now the vaccine dose is to be given to 325 people in 12 institutions across the country. PGIMS practitioners have to dodge 30 people. Out of these, health of about 20 volunteers has been investigated. Six people have been dosed for being found perfectly healthy, while 10 people are awaiting health check report. With the success in Phase One of Part One, doctors hope that the vaccine will be safe even further and may be available to people by the end of the year.

The vaccine is considered to be safe on safety standards'

"The people who were dosed in the first part are completely healthy." Because of this, the vaccine has been considered to meet safety standards. The 20 people who were given doses in the first part will now be given the second dose in the next week.

Corona's vaccine will be given to the people of these cities first!

Scientist advisor and eminent microbiologist Professor K. K. in the Prime Minister's Office (PMO) about the vaccine of the epidemic Covid-19 due to Coronavirus. Vijay Raghavan had said that vaccines should be prepared anywhere in the world, but India's role cannot be denied. This is also true to a large extent, as the Pune-based Indian company Serum Institute of India (SII) is one of the highest vaccine-producing companies in the world. Britain's Oxford University and AstraZeneca have entered into a contract with Serum India for production.

Corona's Vaccine: Big News Human Trial Rohtak PGI Phase I Successful

The AstraZeneca company has been involved in developing the Corona vaccine to Oxford University and Serum Institute has been partnered with the US pharma company AstraZeneca. The vaccine produced by Oxford University will be produced at the Serum Institute in India. The third phase of this vaccine is to be tried on a large scale in India by Serum Institute.

The first and second stage trials of the vaccine at Oxford University, UK, have been successful. Now the third and final phase of this vaccine's human trial is commencing. There will be large scale production of this vaccine in India too. Serum Institute of India (SII) based in Pune, Maharashtra will produce it. By the last week of August, about one crore vaccine doses have been prepared and given. However, the company is in the process of making two to three crore doses.

The scientific name of the vaccine being developed by Oxford University is ChAdOx1 nCoV-19. It is named covid shield. The first and second phase of this vaccine has not been tried in India, but the third and last phase is to be tried in India as well. So, to know how effective this vaccine is on people living in India.

According to the company's CEO Adar Poonawala, permission has been sought from the Drug Controller General of India (DCGI) for the third and final phase trial of the Covid Shield vaccine. Adar Poonawala has said that the Oxford University vaccine has given encouraging results in early stage trials. The next phase of testing in India may begin in mid-August.

The production of the vaccine covid shield by Oxford University will be extensively tried in India after production by the company. According to reports, this vaccine can be introduced to people living in Pune and Mumbai for the first time in the country. According to Serum Institute CEO Adar Poonawala, four to five thousand people living in Pune and Mumbai can be vaccinated during the second-third human trials of the vaccine.

Maharashtra is among the states most affected by the Coronavirus. Many of the corona hotspots have been marked here in the capital city of Mumbai and in the metropolitan Pune, where the pace of corona infection has increased significantly. According to the news, by August in these two cities, about five thousand people can be vaccinated by Covid-19.

Results of the vaccine trial have been published in the medical journal Lancet last week, stating that the vaccine responded well during the trial and does not indicate any serious side effects. The vaccine is producing antibodies and T cells, which are effective in fighting the corona.

Corona's Vaccine: Big News Human Trial Rohtak PGI Phase I Successful

The cost of this vaccine is estimated to be Rs 1000. Adar Poonawala has also said in a statement to the media that his efforts will be to make this vaccine available for less than Rs 1000. However, it is expected that the government in the country will purchase the vaccine and provide it free of cost to the people through vaccination campaign. Here, health experts say that the risk of an epidemic without vaccination will remain.

America doubles investment on Corona's potential vaccine

People all over the world are waiting for the vaccine to get rid of the coronavirus. Meanwhile, the final trial of Moderna's Corona vaccine is going to start in the US from today. Moderna in the US is very close to making the Corona'S vaccine. The final vaccine trials are starting from today. Meanwhile, the Trump government in the US has given $ 472 million to the Moderna company on behalf of the Biomedical Advanced Research and Development Authority (BARDA) to help create the vaccine.

Moderna Inc. reported on Sunday that they had received an additional $ 472 million from the US. The Biomedical Advanced Research and Development Authority (BARDA) on behalf of the government has provided this amount to the company to help in making the Corona'S vaccine. The company has said that this amount will go a long way in the final phase trial of the corona'S vaccine, which starts on July 27.

Earlier, the company had provided a support amount of $ 483 million by the Trump government in the month of April. At that time, his trial of the corona vaccine was in the initial stage. Thus far the Moderna Company has been given $ 955 million from the government of Trump.

Results expected by the end of the year

Corona's first vaccine trial has been conducted in the US, which increases the immunity of people according to the expectation of scientists. The government hopes that its results will be revealed by the end of the year. It is necessary to give two doses of this vaccine at a difference of one month. It has no serious side effects.

Vaccine supplements will come from next year

According to Moderna, the final stage trial of her corona's vaccine will begin on July 27. About 30,000 participants will be involved in this trial. The company has said that it will try to make about 500 million doses of corona's vaccine or about 1 billion doses every year from 2021.

Britain's Imperial College vaccine begins its second trial after Oxford University

After Oxford University, the second phase of the Corona's Vaccine Covasi 1 (COVAC 1) prepared by Britain's Imperial College of London has begun on humans. The UK government has allocated a budget of more than Rs 350 crore for the vaccine to the university. According to the information, in the first phase, the vaccine has been studied on 90 people, in which positive and safe results have been found.

Corona's Vaccine: Big News Human Trial Rohtak PGI Phase I Successful

Now the second phase of the trial will be on 200 people. This vaccine prepared from the genetic material of the virus will be applied in the human body. After this, the outer part of the virus, called the spike protein, will direct the body to activate the immune system and the virus will disappear.

The test will be done in six hospitals ... Phase II of the Imperial College of London vaccine will be tested at six locations. It will include 200 people aged 18 to 75 years. Dr Katrina Pollock, who is leading the trial, says that after the first phase results are better, the vaccine will now be tested on 200 people. Likewise Prof. Robin Shattock says that the results that have been revealed in the first phase have raised our expectations.